Login / Signup

Anti-Listerial Activity of Bacteriocin-like Inhibitory Substance Produced by Enterococcus lactis LBM BT2 Using Alternative Medium with Sugarcane Molasses.

Taciana Freire de OliveiraTaís Mayumi KuniyoshiElionio Galvão FrotaSebastián Bermúdez-PugaLetícia Naomy SakaueLuara Lucena CassianoLeonardo TachibanaRosane Aparecida Moniz PiccoliAttilio ConvertiRicardo Pinheiro de Souza Oliveira
Published in: Antibiotics (Basel, Switzerland) (2024)
Listeria monocytogenes is a foodborne pathogen that contaminates food-processing environments and persists within biofilms on equipment, thus reaching final products by cross-contamination. With the growing demand for clean-label products, the search for natural antimicrobials as biopreservants, such as bacteriocins, has shown promising potential. In this context, this study aimed to evaluate the anti-listerial action of bacteriocins produced by Enterococcus lactis LBM BT2 in an alternative medium containing sugarcane molasses (SCM). Molecular analyses were carried out to characterize the strain, including the presence of bacteriocin-related genes. In the kinetic study on SCM medium E. lactis, LBM BT2 showed biomass and bacteriocin productions similar to those observed on a sucrose-based medium (control), highlighting the potential of the sugarcane molasses as a low-cost substrate. Stability tests revealed that the molecule remained active in wide ranges of pH (4-10) and temperature (60-100 °C). Furthermore, the proteolytic treatment reduced the biomolecule's antimicrobial activity, highlighting its proteinaceous nature. After primary purification by salting out and tangential flow filtration, the bacteriocin-like inhibitory substance (BLIS) showed bacteriostatic activity on suspended L. monocytogenes cells and against biofilm formation at a concentration of 0.625 mg/mL. These results demonstrate the potential of the produced BLIS as a biopreservative in the food industry.
Keyphrases
  • biofilm formation
  • human health
  • candida albicans
  • low cost
  • pseudomonas aeruginosa
  • staphylococcus aureus
  • risk assessment
  • escherichia coli
  • cell cycle arrest
  • combination therapy
  • replacement therapy